{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:44:52Z","timestamp":1775029492640,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The triglyceride glucose index combined with body mass index is a new index that reflects the degree of insulin resistance. In this cross-sectional study, we aimed to explore the predictive value of the triglyceride glucose-body mass index (TyG-BMI) in relation to the occurrence of non-alcoholic fatty liver disease (NAFLD) in the Chinese population with type 2 diabetes (T2D).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We selected 826 patients with T2D who were hospitalized at the Department of Endocrinology and Metabolism of Karamay People\u2019s Hospital from September 2016 to October 2018 for this research. The height, weight, fasting blood glucose, serum insulin, and lipid profiles of the subjects were collected. The liver ultrasound showed any degree of echogenic enhancement of liver tissue and the liver appeared brighter than the renal cortex on ultrasound were considered to be NAFLD. The logistic regression analysis was performed to estimate associations between the triglyceride glucose index (TyG), TyG-BMI index, insulin resistance index (HOMA-IR) and the ratio of the triglycerides to high-density lipoprotein-cholesterol with a diagnosis of NAFLD. The receiver operating characteristic curve method was used to analyze its predictive value for NAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Results of the logistic regression analysis showed that the odds ratios of NAFLD were 6.535 (3.70\u201311.53) and 4.868 (2.576\u20139.200) for the TyG-BMI before and after correction,respectively(<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The area under the curve (AUC) for TyG-BMI was 0.727 (0.691\u20130.764), which was the highest among all the other parameters studied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Compared with the TyG index, the TG\/HDL-C and HOMA-IR, the TyG-BMI was a more effective predictor of NAFLD in T2D.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-022-00993-w","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T05:02:42Z","timestamp":1649998962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Value of the triglyceride glucose index combined with body mass index in identifying non-alcoholic fatty liver disease in patients with type 2 diabetes"],"prefix":"10.1186","volume":"22","author":[{"given":"Nong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiwen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aixia","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiting","family":"Xang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amina","family":"Kirim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"993_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-Jarvinen","year":"2014","unstructured":"Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901\u201310.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"993_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330\u201344.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"993_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.dld.2010.01.016","volume":"42","author":"E Vanni","year":"2010","unstructured":"Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Jarvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42:320\u201330.","journal-title":"Dig Liver Dis"},{"key":"993_CR4","doi-asserted-by":"publisher","first-page":"e0171502","DOI":"10.1371\/journal.pone.0171502","volume":"12","author":"EH van den Berg","year":"2017","unstructured":"van den Berg EH, Amini M, Schreuder TC, Dullaart RP, Faber KN, Alizadeh BZ, et al. Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: a large Dutch population cohort. Plos One. 2017;12:e0171502.","journal-title":"Plos One"},{"key":"993_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3803\/EnM.2016.31.1.86","volume":"31","author":"JI Lee","year":"2016","unstructured":"Lee JI, Kim MC, Moon BS, Song YS, Han EN, Lee HS, et al. The relationship between 10-year cardiovascular risk calculated using the pooled cohort equation and the severity of non-alcoholic fatty liver disease. Endocrinol Metab (Seoul). 2016;31:86\u201392.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"993_CR6","doi-asserted-by":"publisher","unstructured":"Tarantino G, Finelli C, Scopacasa F, et al. Circulating Levels of Sirtuin 4, a Potential Marker of Oxidative Metabolism, Related to Coronary Artery Disease in obese patients suffering from NAFLD, with Normal or Slightly Increased Liver Enzymes. Oxid Med Cell Longev. 2014. https:\/\/doi.org\/10.1155\/2014\/920676 Published online.","DOI":"10.1155\/2014\/920676"},{"key":"993_CR7","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","volume":"158","author":"TG Cotter","year":"2020","unstructured":"Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158:1851\u201364. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.052.","journal-title":"Gastroenterology"},{"key":"993_CR8","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/jgh.12106","volume":"28","author":"MM Smits","year":"2013","unstructured":"Smits MM, Ioannou GN, Boyko EJ, Utzschneider KM. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J Gastroenterol Hepatol. 2013;28:664\u201370.","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"993_CR9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1517\/14728222.2013.789502","volume":"17","author":"A Eguchi","year":"2013","unstructured":"Eguchi A, Povero D, Alkhouri N, Feldstein AE. Novel therapeutic targets for nonalcoholic fatty liver disease. Expert Opin Ther Targets. 2013;17(7):773\u20139. https:\/\/doi.org\/10.1517\/14728222.2013.789502.","journal-title":"Expert Opin Ther Targets"},{"key":"993_CR10","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.1204265","volume":"332","author":"JC Cohen","year":"2011","unstructured":"Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519\u201323.","journal-title":"Science."},{"issue":"2","key":"993_CR11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.cgh.2020.06.048","volume":"19","author":"S Ciardullo","year":"2021","unstructured":"Ciardullo S, Monti T, Perseghin G. Prevalence of liver steatosis and fibrosis detected by transient Elastography in adolescents in the 2017-2018 National Health and nutrition examination survey. Clin Gastroenterol Hepatol. 2021;19(2):384\u2013390.e1. https:\/\/doi.org\/10.1016\/j.cgh.2020.06.048.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"993_CR12","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/j.1440-1746.2005.04058.x","volume":"20","author":"JG Fan","year":"2005","unstructured":"Fan JG, Zhu J, Li XJ, et al. Fatty liver and the metabolic syndromeamong Shanghai adults. J Gastroenterol Hepatol. 2005;20:1825\u201332.","journal-title":"J Gastroenterol Hepatol"},{"key":"993_CR13","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/jgh.12290","volume":"28","author":"J Yan","year":"2013","unstructured":"Yan J, Xie W, Ou WN, et al. Epidemiological survey and risk factoranalysis of fatty liver disease of adult residents, Beijing, China. J Gastroenterol Hepatol. 2013;28:1654\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"993_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2147\/CLEP.S144368","volume":"9","author":"JC Simeone","year":"2017","unstructured":"Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, et al. Clinical course of non-alcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol. 2017;9:679\u201388. https:\/\/doi.org\/10.2147\/CLEP.S144368 eCollection 2017.","journal-title":"Clin Epidemiol"},{"key":"993_CR15","doi-asserted-by":"publisher","first-page":"108358","DOI":"10.1016\/j.diabres.2020.108358","volume":"167","author":"C Stefano","year":"2020","unstructured":"Stefano C, Isabella S, Gianluca P. Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: insights from NHANES 2005\u20132016. Diabetes Res ClinPract. 2020;167:108358. https:\/\/doi.org\/10.1016\/j.diabres.2020.108358 Epub 2020 Jul 31.","journal-title":"Diabetes Res ClinPract"},{"key":"993_CR16","first-page":"E15","volume":"294","author":"R Muniyappav","year":"2008","unstructured":"Muniyappav R, Lee S, Chen H, Quon MJ. Current approachesforassessing insulin sensitivity and resistance in vivo:advantages, limitations, and appropriateusage. Am J Physiel Endoednol Melab. 2008;294:E15\u201326.","journal-title":"Am J Physiel Endoednol Melab"},{"key":"993_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/met.2008.0034","volume":"6","author":"LE Simental-Mendia","year":"2008","unstructured":"Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6:299\u2013304. https:\/\/doi.org\/10.1089\/met.2008.0034.","journal-title":"Metab Syndr Relat Disord"},{"key":"993_CR18","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1210\/jc.2010-0288","volume":"95","author":"F Guerrero-Romero","year":"2010","unstructured":"Guerrero-Romero F, Simental-Mendia LE, Gonzalez-Ortiz M, Martinez-Abundis E, Ramos-Zavala MG, Hernandez-Gonzalez SO, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95:3347\u201351.","journal-title":"J Clin Endocrinol Metab"},{"key":"993_CR19","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/j.diabres.2011.05.030","volume":"93","author":"AC Vasques","year":"2011","unstructured":"Vasques AC, Novaes FS, de Oliveira MS, Souza JR, Yamanaka A, Pareja JC, et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2011;93:e98\u2013e100.","journal-title":"Diabetes Res Clin Pract"},{"key":"993_CR20","first-page":"715","volume":"15","author":"LE Simental-Mendia","year":"2016","unstructured":"Simental-Mendia LE, Simental-Mendia E, Rodriguez-Hernandez H, Rodriguez-Moran M, Guerrero-Romero F. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women. Ann Hepatol. 2016;15:715\u201320.","journal-title":"Ann Hepatol"},{"key":"993_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12944-017-0409-6","volume":"16","author":"S Zhang","year":"2017","unstructured":"Zhang S, Du T, Zhang J, Lu H, Lin X, Xie J, et al. The triglyceride and glucose index (TyG) is an effective biomarker to identify non-alcoholic fatty liver disease. Lipids Health Dis. 2017;16:15.","journal-title":"Lipids Health Dis"},{"key":"993_CR22","doi-asserted-by":"publisher","first-page":"e7041","DOI":"10.1097\/MD.0000000000007041","volume":"96","author":"S Zhang","year":"2017","unstructured":"Zhang S, Du T, Li M, Jia J, Lu H, Lin X, et al. Triglyceride glucose-body mass index is effective in identifying non-alcoholic fatty liver disease in nonobese subjects. Medicine (Baltimore). 2017;96:e7041.","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"993_CR23","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","volume":"142","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592\u2013609.","journal-title":"Gastroenterology"},{"key":"993_CR24","volume-title":"Definition,diagnosis and classification of diabetes mellitus and its complications-Part1:diagnosis and classification of diabetes mellitus","author":"WHO","year":"1999","unstructured":"WHO. Definition,diagnosis and classification of diabetes mellitus and its complications-Part1:diagnosis and classification of diabetes mellitus. Geneva: WHO; 1999."},{"key":"993_CR25","doi-asserted-by":"publisher","unstructured":"Zheng S, Shi S, Ren X, Han T, Li Y, Chen Y, et al. Triglyceride glucose-waist circumference, a novel and effective predictor of diabetes in first-degree relatives of type 2 diabetes patients: cross-sectional and prospective cohort study. J Transl Med. 2016;14(260). https:\/\/doi.org\/10.1186\/s12967-016-1020-8.","DOI":"10.1186\/s12967-016-1020-8"},{"key":"993_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1053\/gast.2002.35354","volume":"123","author":"S Saadeh","year":"2002","unstructured":"Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology. 2002;123:745\u201350.","journal-title":"Gastroenterology"},{"key":"993_CR27","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/hep.26672","volume":"59","author":"AL Birkenfeld","year":"2014","unstructured":"Birkenfeld AL, Shulman GI. Non-alcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59:713\u201323.","journal-title":"Hepatology"},{"key":"993_CR28","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/00042737-200508000-00008","volume":"17","author":"M Machado","year":"2005","unstructured":"Machado M, Cortez-Pinto H. Non-alcoholic fatty liver disease and insulin resistance. Eur J Gastroenterol Hepatol. 2005;17:823\u20136.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"993_CR29","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038\u201348.","journal-title":"Metabolism"},{"key":"993_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12933-014-0146-3","volume":"13","author":"T Du","year":"2014","unstructured":"Du T, Yuan G, Zhang M, Zhou X, Sun X, Yu X. Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. Cardiovasc Diabetol. 2014;13:146. https:\/\/doi.org\/10.1186\/s12933-014-0146-3.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"993_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00125-003-1263-9","volume":"47","author":"A Gastaldelli","year":"2004","unstructured":"Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. San Antonio metabolism study. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia. 2004;47(1):31\u20139. https:\/\/doi.org\/10.1007\/s00125-003-1263-9.","journal-title":"Diabetologia"},{"key":"993_CR32","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/apt.12963","volume":"40","author":"L Fedchuk","year":"2014","unstructured":"Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V, et al. Performance and limitations of steatosis biomarkers in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40:1209\u201322. https:\/\/doi.org\/10.1111\/apt.12963.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"993_CR33","doi-asserted-by":"publisher","first-page":"E863","DOI":"10.1152\/ajpendo.00033.2003","volume":"284","author":"TKT Lam","year":"2003","unstructured":"Lam TKT, Carpentier A, Lewis GF, et al. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol and Metab. 2003;284(5):E863\u201373.","journal-title":"Am J Physiol Endocrinol and Metab"},{"issue":"10","key":"993_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1475-2840-10-93","volume":"17","author":"JK Chiang","year":"2011","unstructured":"Chiang JK, Lai NS, Chang JK, Koo M. Predicting insulin resistance using the triglyceride-to-high-density lipoprotein cholesterol ratio in Taiwanese adults. Cardiovasc Diabetol. 2011;17(10):93. https:\/\/doi.org\/10.1186\/1475-2840-10-93.","journal-title":"Cardiovasc Diabetol"},{"key":"993_CR35","doi-asserted-by":"publisher","unstructured":"Zhang L, Chen S, Deng A, et al. Association between lipid ratios and insulin resistance in a Chinese population. PLoS One. 2015;10(1). https:\/\/doi.org\/10.1371\/journal.pone.0116110.","DOI":"10.1371\/journal.pone.0116110"},{"key":"993_CR36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1172\/JCI10842","volume":"106","author":"BB Kahn","year":"2000","unstructured":"Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473\u201381. https:\/\/doi.org\/10.1172\/JCI10842.","journal-title":"J Clin Invest"},{"issue":"17","key":"993_CR37","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.3748\/wjg.v23.i17.3150","volume":"23","author":"C Gelli","year":"2017","unstructured":"Gelli C, Tarocchi M, Abenavoli L, Di Renzo L, Galli A, De Lorenzo A. Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. World J Gastroenterol. 2017;23(17):3150\u201362.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"993_CR38","doi-asserted-by":"publisher","first-page":"630","DOI":"10.15537\/smj.2019.6.24181","volume":"40","author":"A Al-Saeed","year":"2019","unstructured":"Al-Saeed A. Comments on: serum nesfatin-1 and galanin concentrations in the adult with metabolic syndrome. Relationships to insulin resistance and obesity. Saudi Med J. 2019;40(6):630\u20131.","journal-title":"Saudi Med J"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-00993-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-00993-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-00993-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T05:04:07Z","timestamp":1650085447000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-00993-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["993"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-00993-w","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]},"assertion":[{"value":"3 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of People\u2019s Hospital of Karamay,Informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study did not have competing or any potential competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}